Literature DB >> 21603329

Outside the operating room: unlimited directions in research and beyond.

Ruth Waterman, Aline Betancourt.   

Abstract

The anesthesiologist's role often extends beyond the operating room and includes the realm of research. Recently, interest in investigating mesenchymal stem cells (MSCs) as therapy for myriad diseases has grown. MSCs are adult stem cells traditionally found in bone marrow that hone to damaged tissues and contribute to the tissues' repair by secreting chemokines, cytokines, and extracellular matrix proteins. Research has established a connection between the stimulation of specific Toll-like receptors and the immune-modulating responses of human MSCs, which allows for the polarization of MSCs into either a pro-inflammatory or an anti-inflammatory phenotype. It is anticipated that MSC-based therapies polarized into the anti-inflammatory phenotype will treat painful inflammatory diseases, such as diabetic peripheral neuropathy or rheumatoid arthritis. These new cell-based therapies will be another tool for anesthesiologists to employ while treating patients with chronic pain.

Entities:  

Keywords:  Anti-inflammatory therapy; basic science; mesenchymal stem cells

Year:  2011        PMID: 21603329      PMCID: PMC3096162     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  22 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

Review 2.  Recognition and signaling by toll-like receptors.

Authors:  A Phillip West; Anna Alicia Koblansky; Sankar Ghosh
Journal:  Annu Rev Cell Dev Biol       Date:  2006       Impact factor: 13.827

3.  Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation --- United States, 2007-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-10-08       Impact factor: 17.586

4.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 5.  Endothelial inflammation in insulin resistance.

Authors:  Ake Sjöholm; Thomas Nyström
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

6.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

7.  Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses.

Authors:  Hirokazu Ohtaki; Joni H Ylostalo; Jessica E Foraker; Andrew P Robinson; Roxanne L Reger; Seiji Shioda; Darwin J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-15       Impact factor: 11.205

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 9.  Toll-like receptors and their signaling mechanisms.

Authors:  Shizuo Akira; Shintaro Sato
Journal:  Scand J Infect Dis       Date:  2003

10.  Mesenchymal stem cells avoid allogeneic rejection.

Authors:  Jennifer M Ryan; Frank P Barry; J Mary Murphy; Bernard P Mahon
Journal:  J Inflamm (Lond)       Date:  2005-07-26       Impact factor: 4.981

View more
  1 in total

1.  Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications.

Authors:  Murali Krishna Mamidi; Gurbind Singh; Juani Mazmin Husin; Kavitha Ganesan Nathan; Gopinath Sasidharan; Zubaidah Zakaria; Ramesh Bhonde; Anish Sen Majumdar; Anjan Kumar Das
Journal:  J Transl Med       Date:  2012-11-21       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.